This past April, a piece by R.A. Harrington and a team from Johns Hopkins Bloomberg School of Public Health published in Pediatrics titled “Prenatal SSRI Use and Offspring With Autism Spectrum Disorder or Developmental Delay.” further illustrates the link between prenatal exposure to selective serotonin reuptake inhibitor drugs (SSRIs) and increased risk for

Last summer, Developmental Psychobiology published a piece by S. Brummelte and a team from University of British Columbia (Vancouver) titled “Antidepressant use during pregnancy and serotonin transporter genotype (SLC6A4) affect newborn serum reelin levels.” exploring contributing genetic factors to susceptibility for SSRI-induced birth defects.  To-date, a number of studies have shown that in

A 2005 article in Acta Neurologica Scandinavica by F.J. Vajda and a team from University of Melbourne (Australia) titled “Maternal valproate dosage and foetal malformations.” further elucidates the connection between prenatal exposure to antiepileptic drugs like Depacon and birth defects.  Because the manufacturers (Abbott Laboratories) failed to warn women of this risk in

Published in the January, 2012 edition of Journal of Clinical Neuroscience, an article by F.J. Vajda titled “Teratogenicity of the newer antiepileptic drugs–the Australian experience.” provides important insight into the connection between valproate-containing antiepileptic drugs such as Depacon, Depakene, and Depakote (Abbott Laboratories) and birth defects including spina

Titled “Major malformations in infants exposed to antiepileptic drugs in utero, with emphasis on carbamazepine and valproic acid: a nation-wide, population-based register study.”, a study by K. Wide et al. (2004) further demonstrates knowledge in the medical community that in utero exposure to antiepileptic drugs (AEDs) containing valproate (Depacon, Depakene